

Appendix 4E

Preliminary final report

Rule 4.3A
Introduced 1/1/2003

Name of Entity: Chrysos Corporation Limited
ABN: 76 613 131 141

1. Reporting period ("current period"): Year ended 30 June 2025
Previous corresponding period: Year ended 30 June 2024

2. Results for announcement to the market:

				\$A'000
Revenue	up	46%	to	66,112
Profit / (loss) from ordinary activities after tax attributable to shareholders	down	1,068%	to	(8,223)
Net profit / (loss) for the period attributable to shareholders	down	1,068%	to	(8,223)
Dividends	Amount per share		Franked amount per	
	cents		share cents	
Final	-		-	
Interim	-		-	

Record date for determining entitlements to dividends: N/A

Brief explanation of figures above (if necessary):
N/A

For personal use only

3. Condensed consolidated income statement

	Current Period	Previous corresponding period
	\$A'000	\$A'000
PhotonAssay™ revenue	65,990	44,178
Revenue from consumables	122	1,183
Other income	1,210	2,805
PhotonAssay™ expenses	(15,672)	(10,120)
Employee benefit expenses	(23,624)	(15,587)
Consulting and advisory fees	(1,273)	(1,235)
Consumables cost of sales	(18)	(822)
Travel and marketing costs	(2,484)	(2,131)
IT costs	(2,380)	(1,592)
Other expenses	(4,528)	(4,924)
Depreciation and amortisation expense	(15,261)	(11,439)
Finance costs	(4,962)	(1,996)
Loss before income tax	(2,880)	(1,680)
Income tax benefit/(expense)	(5,343)	976
Loss for the year	(8,223)	(704)
Other comprehensive income for the year		
<i>Items that may be reclassified subsequently to profit or loss</i>		
Exchange differences arising on translation of foreign operations	4,268	-
Total comprehensive loss for the year attributable to the owners from continuing operations	(3,955)	(704)
Revenue & Other Income		
PhotonAssay™ Revenue		
PhotonAssay™ Income – minimum lease payments	55,892	39,494
PhotonAssay™ Income – variable lease payments	10,098	4,684
	65,990	44,178
Revenue from consumables	122	1,183
Other Income		
Government grants	-	25
Interest	1,210	2,780
	1,210	2,805

Expenses:

Loss before income tax includes the following specific expenses:

Depreciation

Property, plant and equipment	944	583
Deployed units	13,049	10,065
	13,993	10,648
Right of use assets	913	505
	14,906	11,153

Amortisation

Intellectual Property	355	286
	355	286
Total Depreciation and Amortisation	15,261	11,439

Finance costs

Interest and finance charges paid/payable on other liabilities	2,732	1923
(Gains)/Losses on foreign exchange	2,135	73
(Gains)/Losses on forward exchange contract	95	-
Finance costs expensed	4,962	1,996

Contributions to defined contribution plans	2,211	1,261
---	-------	-------

For personal use only

4. Condensed Consolidated balance sheet:

	Current Period	Previous corresponding period
	\$A'000	\$A'000
Current assets		
Cash and cash equivalents	21,520	61,067
Trade and other receivables	27,119	16,405
Research and development receivable	588	1,649
Other current assets	3,717	964
Prepayments	11,206	14,299
Total current assets	64,150	94,384
Non-current assets		
Property, plant and equipment	186,115	135,935
Right-of-use assets	4,411	2,187
Intangible assets	6,391	4,178
Other financial assets	100	-
Deferred tax asset	3,143	6,581
Total non-current assets	200,160	148,881
Total assets	264,310	243,265
Current liabilities		
Trade and other payables	34,033	35,880
Lease liabilities	990	214
Employee benefits	5,705	2,165
Other financial liabilities	308	-
Provisions	49	83
Loans and borrowings	2,277	-
Total current liabilities	43,362	38,342
Non-current liabilities		
Lease liabilities	4,463	2,432
Employee benefits	500	196
Other financial liabilities	2,546	4,021
Loans and borrowings	15,137	-
Total non-current liabilities	22,646	6,649
Total liabilities	66,008	44,991
Net assets	198,302	198,274
Equity		
Issued capital	214,261	210,660
Accumulated losses	(21,945)	(14,788)
Reserves	5,986	2,402
Total equity	198,302	198,274

5. Condensed consolidated statement of cash flows

	Current Period	Previous corresponding period
	\$A'000	\$A'000
Net Cash flows from operating activities		
Receipts from customers (inclusive of GST)	65,992	35,165
Payments to suppliers and employees (inclusive of GST)	(54,366)	(33,375)
Government grants	-	25
Interest income	1,210	3,161
Interest paid	(701)	(1,347)
Income tax paid	(3,303)	-
Net cash from operating activities	8,832	3,629
Cash flows from investing activities		
Payments for intangibles	(2,568)	(2,095)
Payments for of property, plant and equipment	(66,154)	(57,768)
Net cash used in investing activities	(68,722)	(59,863)
Cash flows from financing activities		
Proceeds from issue of share capital	2,607	76,948
Transaction costs of issue of share capital	(18)	(3,628)
Proceeds from loan borrowings	18,146	-
Proceeds from lease incentives	440	-
Payment of derivative premium	(100)	-
Repayment of lease liabilities	(1,182)	(567)
Income tax paid	(1,884)	-
Repayment of other borrowings	(732)	(8,454)
Net cash from financing activities	17,277	64,299
Net increase / (decrease) in cash & cash equivalents	(42,613)	(8,065)
Cash & cash equivalents at the beginning of the financial period	61,067	53,359
Effects of exchange rate changes on the balance of cash & cash equivalents in foreign currencies	3,066	(357)
Cash & cash equivalents at the end of the financial period	21,520	61,067

6. Dividends

		Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
		Cents	Cents	Cents
Final Dividend	Current year	-	-	-
	Previous year	-	-	-
Interim Dividend	Current year	-	-	-
	Previous year	-	-	-

Total Dividends on all securities for the year

	Current period	Previous corresponding period
Ordinary securities	116,311,297	115,003,797
Preference securities	-	-
Other equity instruments	-	-
Total	116,311,297	115,003,797

7. Dividend reinvestment plans

The dividend reinvestment plans shown below are in operation:

None

Last date for receipt of election notices for the dividend reinvestment plan: N/A

8. Retained Earnings

	Current period	Previous corresponding period
	\$'000	\$'000
Accumulated Losses at beginning of financial period	(14,788)	(14,084)
Net profit / (loss) attributable to members	(8,223)	(704)
Performance rights lapsed and moved to retained earnings	1,066	-
Accumulated Losses at end of financial period	(21,945)	(14,788)

9. Net Tangible Assets

	Current period	Previous corresponding period
	\$	\$
Net tangible asset backing per ordinary share	1.62	1.63

10. Details of entities which control has been gained or lost

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries in which were incorporated during the financial period:

- PhotonAssay New Zealand Pty Ltd (Incorporated in Australia on 11 October 2024)
- PhotonAssay Operations (Proprietary) Limited (Incorporated in Namibia on 9 September 2024)
- PhotonAssay Mexico S.A.DE C.V. (Incorporated in Mexico on 26 September 2024)

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries over which control was lost during the financial period:

- Chrysos Operations Limited (Deregistered in Tanzania on 18 December 2024)

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Accounting Standards

The financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) other authoritative pronouncements of the Australian Accounting Standards board and the Corporations Act 2001.

14. Results for the period

14.1. Earnings per security

	Current period	Previous corresponding period
	Cents	Cents
Basic loss per share	(7.13)	(0.65)
	Number	Number
Weighted average number of ordinary shares outstanding during the period used in the calculation of basic loss per share	115,316,341	108,746,876

14.2. Returns to shareholders

N/A

14.3. Significant features of operating performances

Continued growth due to deployment of PhotonAssay™ Max Units.

14.4. Segment Results

	Current period	Previous corresponding period
	\$'000	\$'000
Segment Revenues		
APAC	22,896	20,326
EMEA	24,917	17,339
Americas	18,299	7,696
Total Revenues	66,112	45,361
Unallocated interest income	1,210	2,805
Total revenue and other income	67,322	48,166
PhotonAssay™ expenses		
APAC	(6,648)	(3,977)
EMEA	(3,665)	(3,575)
Americas	(5,359)	(2,568)
Total PhotonAssay™ expenses	(15,672)	(10,120)
Segment Depreciation & Amortisation		
APAC	(5,536)	(4,499)
EMEA	(5,166)	(3,120)
Americas	(3,075)	(2,443)
Total of segments Depreciation & Amortisation	(13,777)	(10,062)
Other segment expenses	(18)	(555)
Total segment expenses	(29,467)	(20,737)
Segment Results: Profit before tax		
APAC	10,709	11,618
EMEA	16,071	10,321
Americas	9,865	2,685
Total of segments	36,645	24,624
Reconciliation of reportable segment to profit / (loss) before tax		
Segment profit	36,645	24,624
Central Costs	(39,525)	(26,304)
Profit / (Loss) before tax	(2,880)	(1,680)
Income tax benefit / (expense)	(5,343)	976
Comprehensive profit / (loss) for the period	(8,223)	(704)
Segment Capital Expenditure		
APAC	15,438	-
EMEA	8,532	19,828
Americas	19,751	15,364

	Assets		Liabilities	
	Current period	Previous corresponding period	Current period	Previous corresponding period
	\$'000	\$'000	\$'000	\$'000
APAC – Current	4,772	2,669	219	-
APAC – Total	44,924	25,654	1,349	898
EMEA – Current	9,745	8,671	-	-
EMEA – Total	49,848	46,238	531	531
Americas – Current	5,456	3,780	-	-
Americas – Total	45,724	30,267	884	2,592
Total of Segments	140,496	102,159	2,764	4,021
Unallocated assets	123,814	141,106	63,244	40,970
Total	264,310	243,265	66,008	44,991

14.5. Trends in performance

Both revenue and EBITDA are within the guidance range.

14.6. Other factors affecting current and future results

N/A

15. This report is based on accounts to which one of the following applies

- ✓ The accounts have been audited
- The accounts have been subject to review
- The accounts are in the process of being audited or subject to review
- The accounts have not been audited or reviewed

16. Description of any likely audit dispute or qualification

N/A

Sign here:



Company Director
Dirk Moore Treasure

Date: 25 August 2025